Modelling and optimizing combination therapeutic strategies for KRAS- and EGFR-mutant lung cancer
{{output}}
Non-small cell lung carcinoma (NSCLC) is well-known for its high incidence (about 80% of lung cancer) and genetic heterogeneity. Personalized driver mutations such as EGFR and KRAS have established targeted therapies with kinase inhibitors, whereas immune chec... ...
